Table I.
Patient characteristics.
| Characteristic | n | % |
|---|---|---|
| Age (years) | ||
| ≤53 | 79 | 57.2 |
| >53 | 59 | 42.8 |
| Unknown | 4 | - |
| Menopause state | ||
| Pre-menopause | 45 | 34.6 |
| Post-menopause | 85 | 65.4 |
| Unknown | 12 | - |
| Histological type | ||
| Serous | 110 | 77.5 |
| Mucinous | 12 | 8.5 |
| Clear cell | 8 | 5.6 |
| Transitional | 2 | 1.4 |
| Endometrioid | 2 | 1.4 |
| Undifferentiated | 8 | 5.6 |
| Tumor size (cm) | ||
| ≤5 | 15 | 12.5 |
| 5–10 | 53 | 44.2 |
| >10 | 51 | 43.3 |
| Unknown | 23 | - |
| FIGO stage | ||
| I–II | 31 | 24.4 |
| III–IV | 96 | 75.6 |
| Unknown | 15 | - |
| Node metastasis | ||
| No | 89 | 76.7 |
| Yes | 27 | 23.3 |
| Unknown | 26 | - |
| Location of tumor | ||
| Single side | 56 | 43.4 |
| Both sides | 73 | 56.6 |
| Unknown | 13 | - |
| CA-125 (U/ml) | ||
| 0–35 | 10 | 10.1 |
| 35–500 | 40 | 40.4 |
| 500–1000 | 32 | 32.3 |
| >1000 | 17 | 17.2 |
| Unknown | 43 | - |
| CA19–9 (U/ml) | ||
| 0–37 | 67 | 76.1 |
| 37–100 | 10 | 11.4 |
| >100 | 11 | 12.5 |
| Unknown | 54 | - |
| CEA (ng/ml) | ||
| 0–5 | 72 | 91.1 |
| >5 | 7 | 8.9 |
| Unknown | 63 | - |
| Chemotherapy | ||
| Platinum-based | 111 | 94.9 |
| Non-platinum | 3 | 2.6 |
| No chemotherapy | 3 | 2.6 |
| Unknown | 25 | - |
Unknown: these features were unavailable from the clinical-pathological records of the patients. FIGO, International Federation of Gynecology and Obstetrics; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.